The epigenetic factor CHD4 contributes to metastasis by regulating the EZH2/β-catenin axis and acts as a therapeutic target in ovarian cancer
Abstract Background The overall survival rate of patients with advanced ovarian cancer (OC) has remained static for several decades. Advanced ovarian cancer is known for its poor prognosis due to extensive metastasis. Epigenetic alterations contribute to tumour progression and therefore are of inter...
Main Authors: | Jieyu Wang, Fangfang Zhong, Jun Li, Huiran Yue, Wenzhi Li, Xin Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-01-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12967-022-03854-1 |
Similar Items
-
Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)
by: Guang Lu, et al.
Published: (2023-08-01) -
Romidepsin controls chronic lymphocytic leukemia in a patient with mycosis fungoides
by: David M. Lemchak, et al.
Published: (2016-11-01) -
CHD7 missense variants and clinical characteristics of Chinese males with infertility
by: Leilei Li, et al.
Published: (2020-09-01) -
FBW7-Mediated Degradation of CHD3 Suppresses Hepatocellular Carcinoma Metastasis and Stemness to Enhance Oxaliplatin Sensitivity
by: Shijie Li, et al.
Published: (2024-10-01) -
Recalcitrant Subcutaneous Panniculitis-Like T-Cell Lymphoma Responsive to Histone Deacetylase Inhibitor
by: Laura Gleason, et al.
Published: (2022-12-01)